Back to top
more

Celldex Therapeutics (CLDX)

(Real Time Quote from BATS)

$36.37 USD

36.37
151,557

+0.11 (0.30%)

Updated Apr 26, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CLDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Celldex Therapeutics, Inc. [CLDX]

Reports for Purchase

Showing records 1 - 20 ( 410 total )

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/27/2024

Company Report

Pages: 9

2023 Results; Barzo''s Clinical Profile is on the Rise; A Year of Catalysts Ahead; Reiterate Buy and $80 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/26/2024

Company Report

Pages: 9

Phase 2 CSU Data Don''t Disappoint; Yet Another Reminder, Neutropenia a Non-Event

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/07/2024

Company Report

Pages: 16

Urticaria Focus Piece; Barzolvolimab Has Scratched Our Clinical Data Itch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for CLDX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/06/2023

Company Report

Pages: 11

CSU Phase 2 Nails It; PN Data Expand Barzo''s Profile; Target Increased to $80

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/03/2023

Company Report

Pages: 9

3Q23 Results; Barzo Maintains Steady Progress Across the Board; Phase 2 CSU Topline Data by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/13/2023

Company Report

Pages: 9

Improvements in QoL Top Off Barzolvolimab Phase 1b Trial in CSU; Phase 2 Data by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/09/2023

Company Report

Pages: 8

2Q23 Results; Barzo Advances in Multiple Mast Cell Fronts; CSU and PN Data by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

08/09/2023

Daily Note

Pages: 7

REMIX Phase 3 Data Are a Positive Spin in CSU Space; Barzo Phase 2 Topline Results By YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

07/11/2023

Daily Note

Pages: 10

Phase 2 CSU Trial Pushes Forward Following Patient Enrollment Completion

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

07/06/2023

Daily Note

Pages: 11

Barzo''s Therapeutic Horizon Expands With First Patient Dosed in Phase 2 EoE Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/12/2023

Company Report

Pages: 12

Phase 1b Updates Echo Barzolvolimab´s Ability For Symptom Control in Chronic Urticarias; Phase 2 CSU Data by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/31/2023

Daily Note

Pages: 8

CDX-585 Clinical Journey Commences With First Patient Dosed in Phase 1 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/15/2023

Company Report

Pages: 10

Beyond Barzo; Anti-Inflammatory Pipeline Builds With CDX-622 Bispecific Antibody

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/05/2023

Company Report

Pages: 7

1Q23 Results; Barzolvolimab Continues Making Strides; Top-Line Phase 2 CSU Data Expected by 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/22/2023

Company Report

Pages: 7

Despite Chatter, PN Program Progresses Without Interruption; Phase 1b Data Expected in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/01/2023

Company Report

Pages: 10

2022 Results; Data and Cash Strong With More to Come; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

02/27/2023

Company Report

Pages: 9

Barzolvolimab Continues to Deliver in CSU Phase 1b Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

12/06/2022

Company Report

Pages: 9

Bravo for Barzo

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/10/2022

Company Report

Pages: 7

3Q22 Results; Barzolvolimab Program Continues to Advance; Multiple Data Readouts Expected By 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party